Welcome to our dedicated page for Inogen SEC filings (Ticker: INGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Inogen Inc (INGN) SEC filings page on Stock Titan brings together the company’s regulatory disclosures as a Nasdaq-listed medical technology issuer. Inogen files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, along with other required documents, providing detailed insight into its respiratory care business for the homecare setting.
In its periodic reports, Inogen presents financial statements and operating data covering sales and rental revenue, gross profit, operating expenses such as research and development, sales and marketing, and general and administrative costs, as well as net income or loss, cash flows, and balance sheet information. Supplemental tables may break out revenue by category, including business-to-business domestic and international sales and direct-to-consumer and rental activity, reflecting how its respiratory products reach patients and providers.
Current reports on Form 8-K document material events, such as the release of quarterly financial results and certain leadership or governance changes. For example, Inogen has used Form 8-K to furnish press releases reporting results for quarters ended March 31, June 30, and September 30, 2025, and to describe appointments and designations of executive officers.
On Stock Titan, these filings are updated as they become available from EDGAR and are paired with AI-powered summaries that explain key points in accessible language. Users can quickly see what Inogen reports about its respiratory product portfolio, revenue mix between sales and rentals, operating trends, and significant corporate developments without reading every line of each document.
Investors researching INGN can use this page to access 10-K and 10-Q filings for a structured view of Inogen’s financial condition and risk disclosures, and Form 8-K filings for timely updates on results of operations and notable corporate events, all supported by AI-generated highlights.
Inogen, Inc. is soliciting proxies for its virtual 2026 Annual Meeting of Stockholders to be held June 5, 2026 at 1:00 p.m. Eastern Time. The Board asks holders of the 27,324,616 shares outstanding as of April 6, 2026 to vote on five proposals, including director elections, ratification of Deloitte & Touche LLP, advisory approval of executive compensation, approval of an amended and restated 2023 Equity Incentive Plan, and an amendment to the Charter to declassify the Board.
The proxy highlights a recent operational turnaround with a return to positive Adjusted EBITDA in 2025, a Board-approved share repurchase program, the recent appointment of an independent director Vafa Jamali effective the earlier of the Annual Meeting or June 15, 2026, and a Cooperation Agreement with certain investor parties that includes customary standstill provisions and a 4.99% beneficial ownership limit during its term.
Richardson Jason Andrew reported acquisition or exercise transactions in this Form 4 filing.
Inogen Inc granted Executive Vice President, Chief Financial Officer and Treasurer Jason Andrew Richardson 100,000 restricted stock units on April 6, 2026. Each unit represents a contingent right to receive one share of Inogen common stock.
The award vests over three years, with one-third of the units vesting one year after June 1, 2026, and the remaining two-thirds vesting in equal annual installments on the same calendar date, subject to his continued service.
Inogen Inc filed a Form 3 insider report for Jason Andrew Richardson, who serves as EVP, CFO & Treasurer. The filing data show no reported buy, sell, acquisition, disposition, or derivative transactions, and no derivative positions listed in the summary provided.
Inogen, Inc. reported a governance update centered on a new director and a cooperation agreement with a significant shareholder group. The board appointed medical device veteran Vafa Jamali as a Class I independent director, effective on the earlier of the 2026 annual meeting or June 15, 2026, with his term running to the 2027 annual meeting. He will also join the Audit and Compliance Committees and be paid annual cash fees of $45,000 for board service, $10,000 for the Audit Committee, and $5,000 for the Compliance Committee, plus an initial RSU grant valued at $180,000. Inogen entered into a Cooperation Agreement with Kent Lake entities and Benjamin Natter under which they will vote their shares with the board’s recommendations, are subject to standstill restrictions, and are limited to beneficially owning no more than 4.99% of the company’s voting securities. The agreement runs until shortly before the 2027 nomination deadline or until January 11, 2027, providing a defined period of voting alignment and reduced potential for proxy contests.
Inogen, Inc. announced a leadership transition and new executive hires while reaffirming its first quarter and full-year 2026 financial outlook. Jason Richardson will become Executive Vice President, Chief Financial Officer and Treasurer on April 6, 2026, succeeding Michael Bourque, who will remain as a senior advisor through June 30, 2026.
Richardson’s employment agreement includes a $525,000 annual base salary, a 70% target bonus, $100,000 in cash sign-on and retention bonuses, and equity awards covering 200,000 shares split between time-based and performance-based restricted stock units, with potential overachievement up to 150,000 PSUs. The agreement provides severance and COBRA-related benefits if he is terminated without cause or resigns for good reason, with enhanced salary continuation during a defined change-of-control period.
Inogen also appointed Dominic Hulton as Chief Marketing Officer effective April 1, 2026, and recently added Corey Moritz as Vice President, U.S. Business to Business Sales. The company highlights these appointments as supporting its next phase of growth and notes continued use of its investor relations website for material disclosures.
Inogen, Inc. announced a leadership transition and new executive hires while reaffirming its first quarter and full-year 2026 financial outlook. Jason Richardson will become Executive Vice President, Chief Financial Officer and Treasurer on April 6, 2026, succeeding Michael Bourque, who will remain as a senior advisor through June 30, 2026.
Richardson’s employment agreement includes a $525,000 annual base salary, a 70% target bonus, $100,000 in cash sign-on and retention bonuses, and equity awards covering 200,000 shares split between time-based and performance-based restricted stock units, with potential overachievement up to 150,000 PSUs. The agreement provides severance and COBRA-related benefits if he is terminated without cause or resigns for good reason, with enhanced salary continuation during a defined change-of-control period.
Inogen also appointed Dominic Hulton as Chief Marketing Officer effective April 1, 2026, and recently added Corey Moritz as Vice President, U.S. Business to Business Sales. The company highlights these appointments as supporting its next phase of growth and notes continued use of its investor relations website for material disclosures.
The Vanguard Group filed Amendment No. 10 to a Schedule 13G/A reporting zero beneficial ownership of Inogen Inc common stock. The filing states an Amount beneficially owned: 0 and Percent of class: 0% as reported in the amendment dated 03/13/2026. The filing explains an internal realignment and disaggregation of Vanguard subsidiaries in accordance with SEC Release No. 34-39538 (January 12, 1998), noting certain subsidiaries now report separate beneficial ownership. The signature on the amendment is dated 03/27/2026 and is signed by Ashley Grim, Head of Global Fund Administration.
Inogen Inc executive Mary E. Wright, the VP and Chief Accounting Officer, reported several equity compensation transactions. On March 1, 2026, multiple restricted stock unit tranches, including 1,755, 2,750 and 3,001 units, were exercised or converted into common stock at no cash cost. She also received common stock grants of 1,500 and 1,351 shares, while 675, 520, 1,058 and 1,155 shares of common stock at $6.10 were withheld to cover tax liabilities on the vesting awards. A separate grant of 8,000 restricted stock units was awarded on February 27, 2026, with vesting over several years subject to continued service.
Inogen Inc executive Jennifer M. Yi Boyer reported multiple equity award events. On February 27, 2026, she received a grant of 32,500 restricted stock units, each representing one share of common stock. These units vest in three equal annual installments starting March 1, 2027, subject to continued service.
On March 1, 2026, restricted stock units previously granted fully vested or were earned based on 2025 financial performance, and were converted into common shares. In connection with these vestings, blocks of shares were withheld at $6.10 per share to cover tax liabilities. After these transactions, she directly owned 26,747 shares of Inogen common stock.
Inogen’s Chief Commercial Officer Gregoire Ramade reported equity compensation activity involving restricted stock units and common shares. On March 1, 2026, 13,005 restricted stock units were exercised into 13,005 shares of common stock, and 6,022 shares were withheld at $6.10 per share to cover tax liabilities linked to a vesting award.
On February 27, 2026, Ramade received a new grant of 20,000 restricted stock units, each representing one share of Inogen common stock. One-third of this grant is scheduled to vest on March 1, 2027, with the remaining units vesting in equal annual installments on the same date in subsequent years, subject to continued service.
Inogen Inc executive Kevin P. Smith reported multiple equity compensation transactions. On February 27, 2026, he received a grant of 35,000 restricted stock units (RSUs), each representing the right to receive one share of Inogen common stock, subject to multi-year vesting based on continued service.
On March 1, 2026, 14,005 RSUs were exercised into common stock at no cost, and he was also awarded 1,500 shares of common stock at $6.10 per share. To cover tax withholding related to vested RSUs, 6,276 shares of common stock were disposed of at $6.10 per share. After these transactions, he directly held 22,007 shares of common stock and a remaining RSU balance as reported.